UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 27, 2015
ATHERSYS, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-33876 | 20-4864095 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 3201 Carnegie Avenue, Cleveland, Ohio |
44115-2634 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (216) 431-9900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On January 27, 2015, the Board of Directors of Athersys, Inc. (the “Company”), upon the recommendation of the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), approved the following cash bonuses to the named executive officers of the Company, based on individual performance and achievement of corporate goals in 2014:
| Name |
Title |
Award |
||||
| Dr. Gil Van Bokkelen |
Chief Executive Officer | $ | 133,000 | |||
| William Lehmann, Jr. |
President and Chief Operating Officer | $ | 82,500 | |||
| Dr. John Harrington |
Executive Vice President and Chief Scientific Officer | $ | 82,000 | |||
| Dr. Robert Deans |
Executive Vice President, Regenerative Medicine | $ | 55,000 | |||
| Laura Campbell |
Vice President of Finance | $ | 36,000 | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ATHERSYS, INC. | ||||
| By: | /s/ Laura K. Campbell | |||
| Name: | Laura K. Campbell | |||
| Title: | Vice President of Finance | |||
Date: January 29, 2015